Connect with us

Hi, what are you looking for?

Health

FDA Approves ‘glowing Tumor’ Imaging Drug to Better Identify Ovarian Cancer Cells

The U.S. Food and Drug Administration (FDA) today approved an imaging drug known as Cytalux (pafolacianine), which is attracted to ovarian cancer tissue and illuminates it when exposed to fluorescent light, allowing surgeons to more easily find and more precisely remove the cancer. Physicians at the Center for Precision Surgery in the Abramson Cancer Center at the University of Pennsylvania led one of the largest clinical trial site in the country for the drug, in a partnership with the Indiana-based On Target Laboratories. The approach brings fresh hope to patients diagnosed with ovarian cancer, about half of whom experience a recurrence of their disease after initial treatment. Penn investigators have pioneered targeted technologies for lung, brain, and urinary tract cancers.

Original Article: medicalxpress.com

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Entertainment

Updated: Dec 6, 2021 Original: Dec 6, 2021 Author: Lyndon Abioye Tanya Sam from the Real Housewives of Atlanta is trending on Twitter today,...

Business

This is an editorial about an article originally sourced by 2NEWS. In 2021, OnlineBusiness.com has seen some new trends in digital marketing that may...

Business

HAZLETON — A lone worker loaded his belongings from an open garage at DBi Services’ corporate headquarters on North Conahan Drive Saturday morning. Original...

Movies

Stamford-based NBC Sports will broadcast English Premier League soccer games until 2028, after its parent company agreed on a six-year extension with the league....

CHMO.com